在不同时间点从轻度认知障碍转化为痴呆的神经心理预测因素
Davide Quaranta1, Naike Caraglia1, Federica L'Abbate1
1Neurology Unit, Foundation Policlinico Agostino Gemelli IRCCS, Rome, Italy.
Brain and behavior
|August 8, 2023
概括
语义记忆障碍,特别是语言流性的差异,可能比记忆缺陷更早地预测阿尔茨海默病的进展. 这一发现为轻度认知障碍的早期检测提供了一个新的认知标志物.
科学领域:
- 神经科学是一个神经科学.
- 认知心理学 认知心理学
- 神经学 神经学
背景情况:
- 情节性记忆障碍是预发性阿尔茨海默病 (AD) 的关键标志物.
- 阿尔茨海默病的早期神经病理变化先于临床症状,突出显示出需要超出粉样蛋白 (A),陶病 (T),神经退行 (N) 框架的标志物.
- 当前的临床实践缺乏早期标志物轻度认知障碍 (MCI) 由于AD在记忆力下降变得明显之前.
研究的目的:
- 研究语义记忆评估作为MCI患者AD进展的早期预测器的潜力.
- 确定特定的神经心理测试,可以检测与AD相关的早期认知变化.
- 探索口头流利测试的实用性,包括语音和语义方面的方面,在预测转换到AD.
主要方法:
- 一项纵向研究跟踪了253名MCI受试者6年,监测转化为痴呆症.
- 根据他们进展的时间,被试被分为快速,中间和缓慢的转换者.
- 认知评估包括迷你心理状态考试 (MMSE) 和各种口语流性测试 (类别和语音).
主要成果:
- 稳定的MCI受试者在MMSE,长期记忆和类别口语流性方面表现优于快速转换者.
- 在MMSE和类别口语流性中观察到稳定和中间转换器之间的差异.
- 稳定和缓慢的转换器在MMSE和语音/语义差异得分上有所不同.
结论:
- 早期的语义记忆障碍,由口头流差异表明,可能预测AD演变之前出现插曲性记忆缺陷表现.
- 对语义记忆退化的评估提供了一个有希望的早期认知标记,用于识别AD导致的MCI.
- 与标准测试相比,语音和语义语言流之间的差异可能是早期语义障碍的先进指标.
相关概念视频
Dementia
139
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
139
Cognitive Development During Adulthood
157
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
157
Alzheimer's Disease: Overview
521
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
521
Long-term Depression
2.6K
Long-term depression, or LTD, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTD is the process of synaptic weakening that occurs over time between pre and postsynaptic neuronal connections. The synaptic weakening of LTD works in opposition to synaptic strengthening by long-term potentiation (LTP) and together are the main mechanisms that underlie learning and memory.
Calcium Ion Concentration Mechanism
If over...
Calcium Ion Concentration Mechanism
If over...
2.6K
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
155
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
155


